Biomarkers of Brain-Body Stress Signaling in Psychiatric Disorders

Abstract

The dysregulation of stress signaling between the brain and body is increasingly recognized as a central pathophysiological mechanism in psychiatric disorders. This review synthesizes current evidence on the role of neuroendocrine, inflammatory, and molecular biomarkers reflecting brain-body stress crosstalk in conditions such as depression, anxiety, bipolar disorder, and schizophrenia. We discuss mechanisms underlying these biomarkers, their epidemiological associations, clinical features, diagnostic and therapeutic implications, and emerging research directions for precision psychiatry.

Introduction

Psychiatric disorders are complex and multifactorial, often characterized by a dysregulated response to stress. The brain-body axis, particularly the hypothalamic-pituitary-adrenal (HPA) axis, autonomic nervous system, and immune system, mediates adaptive and maladaptive responses to stressors. Biomarkers reflecting these pathways have garnered interest for their potential to elucidate disease mechanisms, stratify risk, and personalize treatment. This review provides an in-depth analysis of the most clinically relevant biomarkers of brain-body stress signaling in psychiatric illnesses, bridging basic science and clinical practice.

Epidemiology / Disease Burden

Psychiatric disorders such as major depressive disorder (MDD), anxiety disorders, bipolar disorder, and schizophrenia contribute significantly to global disease burden, with depression alone affecting over 280 million people worldwide. Comorbidity with chronic medical conditions, increased disability, and premature mortality are common, often mediated by maladaptive stress responses. Epidemiological studies highlight a strong association between chronic psychosocial stress, allostatic load, and the onset or exacerbation of psychiatric symptoms. Understanding and targeting stress-related biomarkers may help mitigate this burden and improve patient outcomes.

Pathophysiology

Stress activates the HPA axis, resulting in glucocorticoid release (primarily cortisol), as well as the sympathetic-adrenal-medullary (SAM) system, leading to catecholamine secretion. Chronic activation of these pathways induces neuroplastic changes, alters neurotransmitter systems, and provokes inflammatory responses. Dysregulation of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and cortisol is frequently observed in psychiatric populations. Additionally, pro-inflammatory cytokines (e.g., IL-6, TNF-α, CRP) and neurotrophic factors (e.g., BDNF) are implicated in stress-induced neuronal dysfunction and psychiatric symptomatology. These neurobiological changes form the substrate for biomarker discovery and clinical translation.

Risk Factors

Genetic predisposition, early-life adversity, chronic psychosocial stress, and medical comorbidities serve as risk factors for psychiatric disorders and modulate stress signaling pathways. Epigenetic modifications, such as DNA methylation of stress-responsive genes (e.g., NR3C1 encoding the glucocorticoid receptor), further influence vulnerability and biomarker profiles. Environmental exposures interact with genetic background to shape individual trajectories of stress response and psychiatric disease development, emphasizing the need for personalized approaches to biomarker interpretation.

Clinical Features

Patients with psychiatric disorders often exhibit somatic symptoms such as sleep disturbances, fatigue, appetite changes, and autonomic dysfunction reflecting underlying brain-body stress signaling abnormalities. Elevated cortisol, altered diurnal rhythms, increased pro-inflammatory markers, and reduced BDNF are frequently reported in MDD, anxiety, and psychotic disorders. Clinical features such as treatment resistance, suicidality, and cognitive impairment have been linked to specific biomarker profiles, underscoring their clinical relevance.

Diagnosis

While psychiatric diagnoses remain primarily clinical, biomarker assessment is an emerging adjunct. Measurement of salivary or plasma cortisol, ACTH, dexamethasone suppression test (DST), and diurnal variation assessment can aid in characterizing HPA axis function. Inflammatory markers (e.g., CRP, IL-6) and neurotrophic factors (e.g., BDNF) are under investigation for their diagnostic and prognostic utility. Integration of biomarker panels with clinical phenotyping and neuroimaging holds promise for enhancing diagnostic specificity and early detection.

Treatment & Management

Pharmacological interventions targeting stress pathways such as antidepressants, antipsychotics, and anxiolytics can modulate biomarker levels, reflecting treatment response. Adjunctive strategies, including anti-inflammatory agents, glucocorticoid receptor antagonists, and lifestyle interventions (e.g., exercise, mindfulness), have shown promise in normalizing stress biomarkers and improving clinical outcomes. Monitoring biomarkers may inform treatment selection, predict response, and identify risk of relapse or adverse effects, facilitating precision psychiatry.

Recent Advances / Emerging Therapies

Recent advances include the development of multiplex assays for simultaneous quantification of multiple stress biomarkers, machine learning algorithms for biomarker-based prediction, and identification of novel targets such as microRNAs and extracellular vesicles. Emerging therapies targeting inflammation (e.g., cytokine modulators), neurotrophic signaling (e.g., BDNF mimetics), and HPA axis modulation are under investigation. Integration of biomarker data with genomics, proteomics, and neuroimaging is paving the way for a systems biology approach to psychiatric disorders.

Guideline Recommendations

Current guidelines acknowledge the importance of stress and its biomarkers but do not yet endorse routine clinical use due to variability and lack of standardization. The American Psychiatric Association and World Federation of Societies of Biological Psychiatry recommend further research and validation of biomarkers in large, diverse populations. Incorporation of biomarker assessment into clinical trials and stratified medicine frameworks is encouraged to accelerate translation into practice.

Conclusion

Biomarkers of brain-body stress signaling offer valuable insights into the pathophysiology, diagnosis, and management of psychiatric disorders. While significant progress has been made, standardization, validation, and integration into clinical workflows remain challenges. Continued research and multidisciplinary collaboration are essential to realize the full potential of stress biomarkers in transforming psychiatric care through precision medicine.